March 27, 2024
(Industry Intelligence Inc.)
–
Eurofins released a press release on February 27, 2024 that contained highlights from H2 2023. Below are some key points from the release: • Eurofins recorded 8.7% organic core business growth in North America supported by the development of Environment Testing, Food Testing and BioPharma Services. • The company recorded +6.0% organic core business growth driven by strong performance in China, the steady expansion of BioPharma Services in India and new start-up laboratories in Australia and New Zealand. • Development of future biologics products and cell and gene therapies remains at a high level. • Eurofins increased European capacity with a new site in Lyon, France. • The clinical diagnostics segment experienced a strong recovery in volume in 2023 as COVID-19 related impacts have subsided. • During the period, Eurofins accelerated the opening of new blood collection points, with 49 collection points opening in 2023 vs 18 in 2022. • In North America, the BioPharma Services segment recorded strong development due to robust demand for mid-to-late phase biologics development by large- and medium-sized companies. • A high percentage of customers now use Eurofins’ proprietary eLIMS-BPT and LabAccess IT to manage the full life cycle of their testing needs. • Eurofins Discovery has experienced market demand stabilization while demand for Discovery’s expanded biologics has increased. The company reports strong interest for the DiscoveryOne integrated discovery solutions. • In Clinical Diagnostics, Eurofins CellTx, a startup laboratory in Arizona, began operations supporting critical testing for living donor derived human tissue, including stem cells, bone marrow, cord blood, birth tissues, oocytes, and sperm donations. • Eurofins Viracor launched two new notable tests. These include the ExPeCT™ CAR-T multiplexed, real-time qPCR assay that provides a powerful diagnostic tool to monitor and optimize CAR-T therapy for patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas. • Eurofins expanded its Biopharma Services presence in India through scale-up of a recently acquired fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. • In the Middle East, Eurofins acquired its first Clinical Diagnostics business in Saudi Arabia to serve the growing local market. • Eurofins completed the construction of its third differentiated biopharma product testing campus in France, a new 2,000 m² facility in Lentilly. The facility specializes in biopharmaceutical large molecule testing such as biochemistry, biology, microbiology, and virology.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
